In February and March 2023, the FDA approved the immune-checkpoint inhibitors (ICIs) dostarlimab and pembrolizumab, respectively, as monotherapies for women with mismatch-repair-deficient (dMMR) endometrial cancer after platinum-based chemotherapy. Nonetheless, the majority of women with endometrial cancer (70–75%) have mismatch-repair-proficient (pMMR) disease, in which ICIs have also shown promising activity. Now, data from two independent phase III trials demonstrate that the addition of ICIs to chemotherapy extends progression-free survival (PFS) in patients with primary or recurrent disease, regardless of MMR status.